Between Change and Persistence: Material Culture and Consumerism in 16th-century Frankfurt

Based on the analysis of private inventories, testaments, commercial papers, guild statutes, and governmental decrees, this paper discusses the manifestations of material culture and consumerism in 16th-century Frankfurt on the Main. Germany’s imperial city, it hosted fairs twice a year beginning in 1330, emerging in the late Middle Ages as a centre for both commercial and artisanal activities. In the second half of the 16th century, the town – Lutheran since 1533, but de facto multi-confessional after 1547 – became a melting pot of cultures, with a longstanding and steadily expanding Jewish community, and immigration from protestant Walloons and Flemings, among them jewellers, trim makers, and confectioners. Frankfurt, therefore, seems to be an appropriate case study for material culture and consumerism in a 16th-century German town

Mars- plus Europa-INPPS Flagship Missions with High Power Electric Thrusters and Heavy Science Payload

2020/2021 orbit calculations (DLR Bremen + MAI Moscow): 3 Orbits for one non-human MARS/EUROPA-INPPS flagship 1. Orbit Earth (11 Oct 2026) => Mars (28 Jan 2028); 2. Orbit Mars (22 Sept 2028) => Earth (29 Jul 2029); 3. Orbit Earth (12 Oct 2031) => Jupiter / Europa (6 Dec 2035) 22 ETs (for the INPPS flagship CET): example - gridded CET plate with combined ET

Non-Human + Human Deep Space Exploration: By The NEP INPPS Flagship

INPPS Flagship Structure & Subsystems, Ground Based Tests, Pure NEP, International Electric Thrusters, Humans Internationally To Mar

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Lobbyisme économique et mission politique. Les libraires-éditeurs allemands et l’émergence de la société civile au début du XIXe siècle

Les libraires-éditeurs allemands jouèrent dans le processus d’émergence de la société citoyenne au début du XIXe siècle un rôle non négligeable, qui ne se borna pas à la consolidation d’un espace public citoyen. Le secteur du livre a produit en l’éditeur un type de citoyen quasi idéal, dont la contribution à façonner nombre de domaines de la vie peut se comprendre comme un engagement de société civile. Nous allons tenter de montrer par quels intérêts économiques, quelles convictions politique..

Madame de Genlis oder Goethe? Weibliche Autorschaft in französisch- und deutschsprachigen Taschenbüchern für Frauen 1801

International audienc